Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O)

Genovese, MC, Silverman, GJ, Emery, P et al. (7 more authors) (2015) Efficacy and Safety of Tabalumab, an Anti-B-Cell-Activating Factor Monoclonal Antibody, in a Heterogeneous Rheumatoid Arthritis Population Results From a Randomized, Placebo-Controlled, Phase 3 Trial (FLEX-O). JCR: Journal of Clinical Rheumatology, 21 (5). pp. 231-238. ISSN 1076-1608

Abstract

Metadata

Authors/Creators:
  • Genovese, MC
  • Silverman, GJ
  • Emery, P
  • Gupta, RC
  • Gill, A
  • Veenhuizen, M
  • Xie, L
  • Komocsar, WJ
  • Berclaz, P-Y
  • Lee, C
Keywords: BAFF; biologic therapy; rheumatoid; B cell
Dates:
  • Published: August 2015
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Clinical Musculoskeletal Medicine (LIRMM) (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 02 Sep 2016 10:37
Last Modified: 04 Nov 2016 07:26
Published Version: http://dx.doi.org/10.1097/RHU.0000000000000276
Status: Published
Publisher: Lippincott, Williams & Wilkins
Identification Number: https://doi.org/10.1097/RHU.0000000000000276
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics